FI941523L - Menetelmä terapeuttisesti käyttökelpoisen 1-(beta-D-arabinofuranosyyli)-5-propynyyliurasiilin farmaseuttisesti hyväksyttävän emässuolan valmistamiseksi - Google Patents

Menetelmä terapeuttisesti käyttökelpoisen 1-(beta-D-arabinofuranosyyli)-5-propynyyliurasiilin farmaseuttisesti hyväksyttävän emässuolan valmistamiseksi Download PDF

Info

Publication number
FI941523L
FI941523L FI941523A FI941523A FI941523L FI 941523 L FI941523 L FI 941523L FI 941523 A FI941523 A FI 941523A FI 941523 A FI941523 A FI 941523A FI 941523 L FI941523 L FI 941523L
Authority
FI
Finland
Prior art keywords
propynyluracil
arabinofuranosyl
beta
preparing
pharmaceutically acceptable
Prior art date
Application number
FI941523A
Other languages
English (en)
Finnish (fi)
Swedish (sv)
Other versions
FI941523A7 (fi
FI941523A0 (fi
Inventor
Saad George Rahim
Dorothy Jane Martin Purifoy
Original Assignee
Wellcome Found
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Wellcome Found filed Critical Wellcome Found
Priority to FI941523A priority Critical patent/FI941523L/fi
Publication of FI941523A7 publication Critical patent/FI941523A7/fi
Publication of FI941523A0 publication Critical patent/FI941523A0/fi
Publication of FI941523L publication Critical patent/FI941523L/fi

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/04—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/20—Antivirals for DNA viruses
    • A61P31/22—Antivirals for DNA viruses for herpes viruses
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H19/00—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof
    • C07H19/02—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof sharing nitrogen
    • C07H19/04—Heterocyclic radicals containing only nitrogen atoms as ring hetero atom
    • C07H19/06—Pyrimidine radicals

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Molecular Biology (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Virology (AREA)
  • Engineering & Computer Science (AREA)
  • Biotechnology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Epidemiology (AREA)
  • Biochemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Saccharide Compounds (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Developing Agents For Electrophotography (AREA)
  • Apparatus For Radiation Diagnosis (AREA)
  • Silicon Polymers (AREA)
FI941523A 1986-12-15 1987-12-14 Menetelmä terapeuttisesti käyttökelpoisen 1-(beta-D-arabinofuranosyyli)-5-propynyyliurasiilin farmaseuttisesti hyväksyttävän emässuolan valmistamiseksi FI941523L (fi)

Priority Applications (1)

Application Number Priority Date Filing Date Title
FI941523A FI941523L (fi) 1986-12-15 1987-12-14 Menetelmä terapeuttisesti käyttökelpoisen 1-(beta-D-arabinofuranosyyli)-5-propynyyliurasiilin farmaseuttisesti hyväksyttävän emässuolan valmistamiseksi

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
GB868629892A GB8629892D0 (en) 1986-12-15 1986-12-15 Antiviral compounds
FI875487A FI875487A7 (fi) 1986-12-15 1987-12-14 Antivirala foereningar.
FI941523A FI941523L (fi) 1986-12-15 1987-12-14 Menetelmä terapeuttisesti käyttökelpoisen 1-(beta-D-arabinofuranosyyli)-5-propynyyliurasiilin farmaseuttisesti hyväksyttävän emässuolan valmistamiseksi

Publications (3)

Publication Number Publication Date
FI941523A7 FI941523A7 (fi) 1994-03-31
FI941523A0 FI941523A0 (fi) 1994-03-31
FI941523L true FI941523L (fi) 1994-03-31

Family

ID=10609013

Family Applications (2)

Application Number Title Priority Date Filing Date
FI941523A FI941523L (fi) 1986-12-15 1987-12-14 Menetelmä terapeuttisesti käyttökelpoisen 1-(beta-D-arabinofuranosyyli)-5-propynyyliurasiilin farmaseuttisesti hyväksyttävän emässuolan valmistamiseksi
FI875487A FI875487A7 (fi) 1986-12-15 1987-12-14 Antivirala foereningar.

Family Applications After (1)

Application Number Title Priority Date Filing Date
FI875487A FI875487A7 (fi) 1986-12-15 1987-12-14 Antivirala foereningar.

Country Status (30)

Country Link
US (1) US5079235A (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
EP (3) EP0417560A1 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
JP (2) JPS63165397A (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
KR (1) KR880007521A (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
CN (2) CN87108265A (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
AT (1) ATE88713T1 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
AU (2) AU601529B2 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
CA (1) CA1319143C (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
CS (3) CS275398B2 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
DD (2) DD264924A5 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
DE (1) DE3785651T2 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
DK (2) DK654287A (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
ES (1) ES2054693T3 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
FI (2) FI941523L (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
GB (1) GB8629892D0 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
HU (4) HU202112B (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
IE (2) IE930471L (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
IL (3) IL95141A (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
LT (1) LT2064B (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
LV (1) LV5273A3 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
MC (1) MC1882A1 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
MX (1) MX9203216A (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
NO (1) NO167576C (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
NZ (1) NZ222898A (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
PH (2) PH24104A (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
PL (3) PL158050B1 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
PT (1) PT86356B (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
RU (1) RU2036199C1 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
SU (1) SU1731064A3 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
ZA (1) ZA879382B (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)

Families Citing this family (40)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2828642B2 (ja) * 1987-06-24 1998-11-25 ハワード フローレイ インスティテュト オブ イクスペリメンタル フィジオロジー アンド メディシン ヌクレオシド誘導体
US4954485A (en) * 1987-10-20 1990-09-04 Sanyo-Kokusaku Pulp Co., Ltd. 2',3'-dideoxy-4-thio-uridine derivatives, process for their preparation and antivirus agents using them
EP0346108A3 (en) * 1988-06-09 1991-04-24 The Wellcome Foundation Limited Anti-infective nucleosides
US5157114A (en) * 1988-08-19 1992-10-20 Burroughs Wellcome Co. 2',3'-dideoxy-3'-fluoro-5-ethyngluridine
GB8827339D0 (en) * 1988-11-23 1988-12-29 Wellcome Found Antiviral compounds
US5006646A (en) * 1989-02-22 1991-04-09 Yuki Gosei Kogyo Co., Ltd. Process for preparing 2'-deoxy-5-trifluoromethyl-beta-uridine
IE902574A1 (en) * 1989-07-17 1991-02-27 Univ Birmingham Antiviral pyrimidine nucleosides
DD293498A5 (de) * 1989-07-20 1991-09-05 Zi Fuer Molekularbiologie Der Adw,De Verfahren zur herstellung eines mittels fuer die behandlung oder prophylaxe von hepatits-infektionen bei mensch und tier
US6337209B1 (en) 1992-02-26 2002-01-08 Glaxo Wellcome Inc. Molecular constructs containing a carcinoembryonic antigen regulatory sequence
GB8919607D0 (en) * 1989-08-30 1989-10-11 Wellcome Found Novel entities for cancer therapy
GB9008696D0 (en) * 1990-04-18 1990-06-13 Wellcome Found Anti-viral compounds
GB9012899D0 (en) * 1990-06-09 1990-08-01 Wellcome Found Anti-hbv pyrimidine nucleoside
GB9014618D0 (en) * 1990-06-30 1990-08-22 Wellcome Found Process for the preparation of pyrimidine nucleosides
US5643913A (en) * 1990-07-19 1997-07-01 Glaxo Wellcome Inc. Pharmaceutical compositions of 5-substituted uracil compounds
DE69128626T2 (de) 1990-07-19 1998-05-20 The Wellcome Foundation Ltd., Greenford Enzyminaktivatoren
GB9020930D0 (en) 1990-09-26 1990-11-07 Wellcome Found Pharmaceutical combinations
GB9104165D0 (en) * 1991-02-27 1991-04-17 Wellcome Found Novel entities for hiv therapy
GB9111580D0 (en) * 1991-05-30 1991-07-24 Wellcome Found Nucleoside derivative
US5646123A (en) * 1991-06-10 1997-07-08 Alberta Research Council Time dependent administration of oligosaccharide glycosides related to blood group determinants having a type I or type II core structure in reducing inflammation in a sensitized mammal arising form exposure to an antigen
US5580858A (en) * 1991-06-10 1996-12-03 Alberta Research Council Immunosuppressive and tolerogenic modified Lewisx compounds
HU207524B (en) * 1991-11-22 1993-04-28 Mta Koezponti Kemiai Kutato In Industrial process for producing 5-alkyl-2'-deoxy-beta-uridines with stereoselective synthesis
US5484908A (en) * 1991-11-26 1996-01-16 Gilead Sciences, Inc. Oligonucleotides containing 5-propynyl pyrimidines
US6235887B1 (en) 1991-11-26 2001-05-22 Isis Pharmaceuticals, Inc. Enhanced triple-helix and double-helix formation directed by oligonucleotides containing modified pyrimidines
TW393513B (en) * 1991-11-26 2000-06-11 Isis Pharmaceuticals Inc Enhanced triple-helix and double-helix formation with oligomers containing modified pyrimidines
EP1256589A3 (en) * 1991-11-26 2003-09-17 Isis Pharmaceuticals, Inc. Oligomers containing modified pyrimidines
JP2823358B2 (ja) * 1992-05-26 1998-11-11 アルバータ リサーチ カウンスル 免疫抑制性および寛容原性修飾ルイス▲上ｃ▼およびＬａｃＮＡｃ化合物
CA2119315A1 (en) * 1993-03-18 1994-09-19 Tsujiaki Hata Nucleoside derivatives and anti-herpes composition
US6432924B1 (en) 1993-12-26 2002-08-13 East Carolina University Method of treating disorders characterized by overexpression of cytidine deaminase or deoxycytidine deaminase
WO1996018636A1 (fr) * 1994-12-13 1996-06-20 Taiho Pharmaceutical Co., Ltd. Derives de nucleoside substitues en 3'
WO1997023230A1 (en) * 1995-12-22 1997-07-03 East Carolina University Method of treating disorders characterized by overexpression of cytidine deaminase or deoxycytidine deaminase
WO1997027849A1 (fr) * 1996-02-02 1997-08-07 Showa Shell Sekiyu K.K. Medicaments pour traiter les infections provoquees par le virus de l'herpes et compositions preventives pour empecher un retour de l'infection, contenant tous les deux des derives triterpeniques comme principe actif
CN1911237B (zh) * 1998-08-10 2010-09-15 艾丹尼克斯(开曼)有限公司 用于治疗乙型肝炎的β-L-2＇-脱氧-核苷
US6653318B1 (en) 1999-07-21 2003-11-25 Yale University 5-(E)-Bromovinyl uracil analogues and related pyrimidine nucleosides as anti-viral agents and methods of use
US7019129B1 (en) 2000-05-09 2006-03-28 Biosearch Technologies, Inc. Dark quenchers for donor-acceptor energy transfer
AU2002360697B2 (en) 2001-12-20 2009-04-23 Beth Israel Deaconess Medical Center Treatment of EBV and KHSV infection and associated abnormal cellular proliferation
JP2008521930A (ja) 2004-12-03 2008-06-26 アドヘレックス テクノロジーズ， インコーポレイテッド ５−ｆｕおよび５−ｆｕプロドラッグと併用してｄｐｄ阻害物質を投与するための方法
US8466266B2 (en) 2008-04-01 2013-06-18 Biosearch Technologies, Inc. Stabilized nucleic acid dark quencher-fluorophore probes
CN101768197A (zh) * 2008-12-29 2010-07-07 北京德众万全药物技术开发有限公司 一种奈拉滨的制备方法
CA2777546C (en) 2009-10-14 2019-11-05 Adherex Technologies, Inc. Treating neurotoxicity associated with combinations of 5-fu or its prodrugs and dpd inhibitors
DK3126517T3 (da) * 2014-03-30 2020-01-20 Cepheid Modificerede cytosin-polynukleotid-oligomere og fremgangsmåder

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB1601020A (en) * 1978-04-24 1981-10-21 Stichting Grega Vzw 2'-deoxy-5 (2-halogenovinyl)-uridines
US4211773A (en) * 1978-10-02 1980-07-08 Sloan Kettering Institute For Cancer Research 5-Substituted 1-(2'-Deoxy-2'-substituted-β-D-arabinofuranosyl)pyrimidine nucleosides
US4267171A (en) * 1979-07-02 1981-05-12 The Regents Of The University Of California C-5 Substituted cytosine nucleosides
US4247544A (en) * 1979-07-02 1981-01-27 The Regents Of The University Of California C-5 Substituted uracil nucleosides
US4274544A (en) * 1980-03-11 1981-06-23 The Continental Group, Inc. Single-piece plastic closure having integral seal forming means
EP0082668A1 (en) * 1981-12-18 1983-06-29 Beecham Group Plc 5-(2-Halogenovinyl)-2'-deoxyuridine derivatives, processes for their preparation, pharmaceutical compositions containing them and their use in treating viral infections
EP0082667A1 (en) * 1981-12-18 1983-06-29 Beecham Group Plc Pharmaceutical compositions
EP0095294A1 (en) * 1982-05-22 1983-11-30 Beecham Group Plc Deoxyuridine compounds, methods for preparing them and their use in medicine
EP0097039A1 (en) * 1982-06-16 1983-12-28 Beecham Group Plc 5-(E-2-halovinyl)-2'-deoxyuridine derivatives, processes for their preparation, pharmaceutical compositions containing them, and their use in treating viral infections
GB8517402D0 (en) * 1985-07-10 1985-08-14 Wellcome Found Treatment of viral infections
DK167377B1 (da) * 1985-09-17 1993-10-25 Wellcome Found 3'-azidopyrimidinnucleosider eller farmaceutisk acceptable salte eller estere deraf til anvendelse ved behandling af eller profylakse for en human retrovirusinfektion
SE8701605D0 (sv) * 1987-04-16 1987-04-16 Astra Ab Novel medicinal compounds

Also Published As

Publication number Publication date
NO167576C (no) 1991-11-20
JPH0378370B2 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html) 1991-12-13
HUT46336A (en) 1988-10-28
CS916187A2 (en) 1991-02-12
CN87108265A (zh) 1988-07-13
FI875487A0 (fi) 1987-12-14
CS275402B6 (en) 1992-02-19
FI941523A7 (fi) 1994-03-31
GB8629892D0 (en) 1987-01-28
AU8252187A (en) 1988-06-16
AU626041B2 (en) 1992-07-23
PH24104A (en) 1990-03-05
PL160321B1 (pl) 1993-02-26
HU199867B (en) 1990-03-28
PL160322B1 (pl) 1993-02-26
SU1731064A3 (ru) 1992-04-30
KR880007521A (ko) 1988-08-27
AU5989090A (en) 1990-11-08
MX9203216A (es) 1992-07-01
HU207735B (en) 1993-05-28
HU903829D0 (en) 1990-11-28
PL269462A1 (en) 1989-06-26
LV5273A3 (lv) 1993-10-10
HU202112B (en) 1991-02-28
NZ222898A (en) 1990-12-21
IL95141A0 (en) 1991-06-10
EP0417560A1 (en) 1991-03-20
IL84810A0 (en) 1988-06-30
PL158050B1 (pl) 1992-07-31
CS767588A3 (en) 1991-02-12
ZA879382B (en) 1989-08-30
JPH03141292A (ja) 1991-06-17
IE930471L (en) 1988-06-15
ATE88713T1 (de) 1993-05-15
IE930470L (en) 1988-06-15
FI941523A0 (fi) 1994-03-31
RU2036199C1 (ru) 1995-05-27
NO875209L (no) 1988-06-16
DE3785651D1 (de) 1993-06-03
MC1882A1 (fr) 1989-01-24
EP0272065B1 (en) 1993-04-28
ES2054693T3 (es) 1994-08-16
US5079235A (en) 1992-01-07
PT86356A (en) 1988-01-01
CS342591A3 (en) 1992-04-15
PT86356B (pt) 1990-11-07
EP0272065A2 (en) 1988-06-22
DK654287A (da) 1988-06-16
DD274766A5 (de) 1990-01-03
DK169991D0 (da) 1991-10-04
PL277927A1 (en) 1989-08-21
CN1080292A (zh) 1994-01-05
CS275398B2 (en) 1992-02-19
DK169991A (da) 1991-10-04
HU200932B (en) 1990-09-28
CA1319143C (en) 1993-06-15
NO875209D0 (no) 1987-12-14
PL277926A1 (en) 1989-08-21
IL95141A (en) 1992-05-25
EP0272065A3 (en) 1988-11-17
DK654287D0 (da) 1987-12-14
DK168323B1 (da) 1994-03-14
DD264924A5 (de) 1989-02-15
PH24870A (en) 1990-12-26
DE3785651T2 (de) 1993-11-11
EP0486477A2 (en) 1992-05-20
FI875487A7 (fi) 1988-06-16
IL84810A (en) 1992-05-25
LT2064B (lt) 1993-06-15
JPS63165397A (ja) 1988-07-08
NO167576B (no) 1991-08-12
AU601529B2 (en) 1990-09-13
EP0486477A3 (en) 1992-06-17

Similar Documents

Publication Publication Date Title
FI941523A7 (fi) Menetelmä terapeuttisesti käyttökelpoisen 1-(beta-D-arabinofuranosyyli)-5-propynyyliurasiilin farmaseuttisesti hyväksyttävän emässuolan valmistamiseksi
FI881180L (fi) Menetelmä terapeuttisesti käytettävien tetrahydronaftaleenijohdannaisten valmistamiseksi
FI883050L (fi) Menetelmä terapeuttisesti aktiivisten pyranoindolitsinokinoliinijohdannaisten valmistamiseksi
FI893738L (fi) Menetelmä terapeuttisesti käyttökelpoisen bradykiniiniantagonistin valmistamiseksi
FI885409A7 (fi) Menetelmä uusien terapeuttisesti käyttökelpoisten pyridatsiiniamiinijohdannaisten valmistamiseksi
FI870903L (fi) Menetelmä terapeuttisesti aktiivisten alfa-heterosykleillä substituoitujen tolunitriilien valmistamiseksi
FI884636L (fi) Pitkävaikutteisen farmaseuttisen valmisteen valmistusmenetelmä
FI893433A7 (fi) Menetelmä terapeuttisesti käyttökelpoisten heterosyklisten yhdisteiden valmistamiseksi
FI883744L (fi) Menetelmä valmistaa farmaseuttisesti käyttökelpoisia indolijohdoksia
FI883426L (fi) Menetelmä terapeuttisesti käyttökelpoisen pentasakkaridin valmistamiseksi
FI890282L (fi) Menetelmä terapeuttisesti käyttökelpoisten 23,24-didehydro-25-hydroksikalsiferolijohdannaisten valmistamiseksi
FI882418A7 (fi) Menetelmä valmistaa terapeuttisesti aktiivisia syklisiä amiinijohdannaisia
FI893448L (fi) Menetelmä valmistaa terapeuttisesti aktiivinen ranitidiinisuola
FI892497L (fi) Menetelmä terapeuttisesti aktiivisten bentsamidijohdannaisten valmistamiseksi
FI892182A7 (fi) Menetelmä terapeuttisesti käyttökelpoisten kromaanijohdannaisten valmistamiseksi
FI890286A0 (fi) Menetelmä terapeuttisesti käyttökelpoisten dideoksikarbosyklisten nukleosidianalogien valmistamiseksi
FI875666L (fi) Menetelmä terapeuttisesti aktiivisen kinoliiniyhdisteen valmistamiseksi
FI894693L (fi) Menetelmä valmistaa farmaseuttisesti arvokasta imidatsoliinijohdannaista
FI890283A7 (fi) Menetelmä terapeuttisesti käyttökelpoisten 25-hydroksi-vitamiinin D-johdannaisten valmistamiseksi
FI891339A7 (fi) Menetelmä uusien terapeuttisesti käyttökelpoisten aristeromysiini/adenosiinijohdannaisten valmistamiseksi
FI894803L (fi) Menetelmä terapeuttisesti käyttökelpoisten kinolinonijohdannaisten valmistamiseksi
FI884471A7 (fi) Menetelmä terapeuttisesti aktiivisten dihydropyridiinijohdannaisten valmistamiseksi
FI884910A7 (fi) Menetelmä terapeuttisesti käyttökelpoisten bentsopyraanijohdannaisten valmistamiseksi
FI890123L (fi) Menetelmä valmistaa terapeuttisesti vaikuttavia indolyylipiperidiiniyhdisteitä
FI892948A7 (fi) Menetelmä terapeuttisesti käyttökelpoisten kromaanijohdannaisten valmistamiseksi

Legal Events

Date Code Title Description
FD Application lapsed